National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$21.00
add to cart

Rights & Permissions

topleft topright

Final Report of The National Academies' Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to The National Academies' Guidelines for Human Embryonic Stem Cell Research (2010)
Board on Life Sciences (BLS)
Board on Health Sciences Policy (HSP)

Citation Manager

. "Appendix C: National Academies' Guidelines for Human Embryonic Stem Cell Research, Amended as of May 2010." Final Report of The National Academies' Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to The National Academies' Guidelines for Human Embryonic Stem Cell Research. Washington, DC: The National Academies Press, 2010.

Please select a format:

BibTeX EndNote RefMan


Page
31
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Final Report of the National Academies’ Human Embryonic Stem Cell Research Advisory Committee and 2010 Amendments to the National Academies’ Guidelines for Human Embryonic Stem Cell Research
  1. A copy of the donor consent form.

  2. Proof of Institutional Review Board approval of the procurement process.

  3. Available medical information on the donors, including results of infectious-disease screening.

  4. Available clinical, observational, or diagnostic information about the donor(s).

  5. Critical information about culture conditions (such as media, cell passage, and safety information).

  6. Available cell line characterization (such as karyotype and genetic markers).

A repository has the right of refusal if prior culture conditions or other items do not meet its standards.

  1. A secure system for protecting the privacy of donors when materials retain codes or identifiable information, including but not limited to

    1. A schema for maintaining confidentiality (such as a coding system).

    2. A system for a secure audit trail from primary cell lines to those submitted to the repository.

    3. A policy governing whether and how to deliver clinically significant information back to donors.

  1. The following standard practices:

    1. Assignment of a unique identifier to each sample.

    2. A process for characterizing cell lines.

    3. A process for expanding, maintaining, and storing cell lines.

    4. A system for quality assurance and control.

    5. A website that contains scientific descriptions and data related to the cell lines available.

    6. A procedure for reviewing applications for cell lines.

    7. A process for tracking disbursed cell lines and recording their status when shipped (such as number of passages).

    8. A system for auditing compliance.

    9. A schedule of charges.

    10. A statement of intellectual property policies.

    11. When appropriate, creation of a clear Material Transfer Agreement or user agreement.

    12. A liability statement.

    13. A system for disposal of material.

Page
31